the Pharmacokinetic Profiles of Linagliptin With DW1029M
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: DW1029M 1200mg and Linagliptin 5mg
- Registration Number
- NCT02212782
- Lead Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
- Brief Summary
Phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Linagliptin after oral administration in healthy male volunteer.
- Detailed Description
A Randomized, open-label, multiple-dose, crossover phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Linagliptin after oral administration in healthy male volunteer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
- A healthy adult within the range of 19 to 55 years old at the time of screening
- Body Mass Index(BMI)=17.5~30.5kg/m2, one with weight of more than 55kg (BMI= kg/(m)2)
- Congenital or chronic diseases within the last three years, there is no medical examination results of popular characters with no psychotic symptoms or findings
- Doctor checks conducted hematology, blood chemistry, urinalysis and laboratory tests, including an electrocardiogram(EKG) performed during screening tests such as a suitable test subjects who judged
- The purpose of the test participants prior to testing, information, and to hear about the free will fully explain to participate in this study, according to the Institutional Review Board(IRB)-approved consent form signed by the parties in writing
Exclusion Criteria
- one with clinically significant blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic disease (but ,except for untreated seasonal allergies of asymptomatic at the time of administration) with medical history or evidence
- one with gastrointestinal disease(Such as esophageal stricture or achalasia of the esophagus disease, Crohn disease) to affect drug absorption or surgery(but, excluding simple appendectomy or hernia surgery) with medical history
- Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) > 2 times the upper limit of the normal range
- Within 6 months, 210 g / week of alcohol in excess of a history of regular characters (beer (5%) 1 cup (250 mL) = 10 g, soju(20%) 1 cup (50 mL) = 8 g, Wine (12%) 1 cup (125 mL) = 12 g)
- Take part in other clinical trials within two months
- Systolic Blood Pressure(SBP) ≥ 140 mmHg or Diastolic Blood Pressure (DBP) ≥ 90 mmHg
- The great history of alcohol or drug abuse within 1 year
- Taking medication of drug-metabolizing enzymes that are known to significantly induce or inhibit within 30 days
- More than 20 cigarettes a day smoker
- Taking medication of a prescription drug or nonprescription within 10 days,
- Within two months the whole blood donation have, within one month of the apheresis donation have
- Participate in clinical trials to test drug administration and may be at increased risk due to interpretation of test results, or may interfere with severe supply / chronic medical or mental condition or abnormal laboratory test values in character
- Patient with hypersensitivity to investigational products or ingredients
- Patient with Type 1 Diabetes or Diabetic ketoacidosis
- Described lifestyle in this protocol can comply with or can not
- One with other investigator judge to unsuitable
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description B Group DW1029M 1200mg and Linagliptin 5mg 1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg A Group Linagliptin 5mg 1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg A Group DW1029M 1200mg and Linagliptin 5mg 1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg B Group Linagliptin 5mg 1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg
- Primary Outcome Measures
Name Time Method Cmax and AUC 1st day and 43rd day, 5th day and 47th day, 6th day and 48th day : Predose(0, morning), 7th day and 49th day : Predose(0), 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour Maximum of Concentration(Cmax), Area Under Plasma Concentration-Time Curve(AUC)
- Secondary Outcome Measures
Name Time Method Pharmacokinetic Profile of Plasma 1st day and 43rd day, 5th day and 47th day, 6th day and 48th day : Predose(0, morning), 7th day and 49th day : Predose(0), 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour Maximum drug concentration time(Tmax), Half-time(t1/2), Apparent renal clearance(CL/F), Apparent volume of distribution(Vd/F), Fluctuation\[(Css,max-Css,min)/Css,av\], Swing\[(Css,max-Css,min)/Css,min\]
Trial Locations
- Locations (1)
Chonbuk National University Hospital
🇰🇷Jeonju, Jeollabukdo, Korea, Republic of